Janssen Research & Development, LLC

Birmingham, Alabama

OncologyFiled/ApprovedListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Feb 10, 2025
Thrombocytopenia, Neonatal Alloimmune · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
ClinicalTrials.gov · NCT06533098 (opens the source filing in a new tab)
Trial
Study registered
Feb 3, 2025
Adenomatous Polyposis Coli · NO_LONGER_AVAILABLE · sponsor: Janssen Research & Development, LLC · Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
ClinicalTrials.gov · NCT04948398 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 11, 2024
Thrombocytopenia, Neonatal Alloimmune · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
ClinicalTrials.gov · NCT06449651 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 26, 2024
Depressive Disorder, Major, Anhedonia · TERMINATED · sponsor: Janssen Research & Development, LLC · A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
ClinicalTrials.gov · NCT06514742 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 25, 2022
Multiple Myeloma · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov · NCT05552222 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 4, 2022
Leukemia, Myeloid, Acute · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
ClinicalTrials.gov · NCT05453903 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 17, 2021
Healthy Non-dependent, Recreational Sedative Users, Abuse Potential · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
ClinicalTrials.gov · NCT05106153 (opens the source filing in a new tab)
Trial
PHASE4 registered
Dec 10, 2021
Crohn Disease · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov · NCT05029921 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 17, 2021
Arthritis, Psoriatic · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ClinicalTrials.gov · NCT04882098 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 12, 2021
Multiple Myeloma · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
ClinicalTrials.gov · NCT04722146 (opens the source filing in a new tab)
Trial
PHASE4 registered
Nov 4, 2020
Depressive Disorder, Treatment-Resistant · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
ClinicalTrials.gov · NCT04599855 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 11, 2019
Prostatic Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ClinicalTrials.gov · NCT03767244 (opens the source filing in a new tab)
Trial
PHASE2 registered
Oct 5, 2017
Depressive Disorder, Major · COMPLETED · sponsor: Janssen Research & Development, LLC · Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
ClinicalTrials.gov · NCT03185819 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 20, 2017
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants
ClinicalTrials.gov · NCT03127189 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 9, 2016
Renal Insufficiency · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
ClinicalTrials.gov · NCT02961660 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 7, 2016
Depressive Disorder, Major · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder
ClinicalTrials.gov · NCT02919579 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 3, 2016
Tuberculosis, Multidrug-Resistant · RECRUITING · sponsor: Janssen Research & Development, LLC · Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
ClinicalTrials.gov · NCT02354014 (opens the source filing in a new tab)
Trial
PHASE1 registered
May 1, 2016
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants
ClinicalTrials.gov · NCT02816853 (opens the source filing in a new tab)
Trial
PHASE1 registered
May 1, 2016
Healthy · COMPLETED · sponsor: Janssen Research & Development, LLC · Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants
ClinicalTrials.gov · NCT02824315 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 9, 2015
Immunoassay, Antipsychotic · COMPLETED · sponsor: Janssen Research & Development, LLC · Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
ClinicalTrials.gov · NCT02634463 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 23, 2015
Depressive Disorder, Major · COMPLETED · sponsor: Janssen Research & Development, LLC · An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
ClinicalTrials.gov · NCT02473289 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.78name similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Guselkumab in Participants With Active Psoriatic Arthritis
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
5mo agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
10mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
11mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
11mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase II trial registered: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder
Apr 2025Trial completedSource (opens the source filing in a new tab)
Filed/Approved trial registered: A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants
Feb 2025Trial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Feb 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

Study registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE4 registered

PHASE3 registered

PHASE1 registered

PHASE4 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE2 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE2 registered